Komori
Susmed (4263) · InitiativeAdvanced

Strengthening Incentives to Improve Medium- to Long-Term Performance and Corporate Value Through the Issuance of Employee Stock Options

First written in FY2024-Q3. 7 of 8 entries say "Advanced", first in FY2024. Latest entry: FY2026.

8entries
3years
4from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2024-Q3AdvancedFY2024 – FY20262024: 220242025: 120252026: 52026
Same theme, other companies
Grant and Issuance of Equity Compensation to Employees and Officers (Stock Options and Restricted Stock)A theme 658 companies write about · 0 as a headwind · 739 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 179 companies compared. The sentences above are computed from all 179.Comparing 200 of the theme's 741 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2026AdvancedAnnual report

    「13th Series of Stock Acquisition Rights Date of resolution 22 July 2026 Category and number of eligible persons (people) Company employees 43 Number of stock acquisition rights (units) ※ 1,330 (Note 1) Number of shares underlying the stock acquisition rights (shares) ※ 133,000 (Note 1)」

    On 22 July 2026, the company issued the 13th Series of Stock Acquisition Rights covering 133,000 shares to 43 employees.
  2. FY2025AdvancedAnnual report

    「Series 12 stock acquisition rights Resolution date 17 July 2025 Eligible recipients and number (people) Company employees 35 Number of stock acquisition rights (units) ※ 1,175 (Note) 1 Number of shares underlying the stock acquisition rights (shares) ※ 117,500 (Note) 1」

    As of 17 July 2025, after the filing, the Company issued Series 12 stock acquisition rights covering 117,500 shares to 35 employees. The Company is expanding its long-term incentive program for employees to improve performance and corporate value.
  3. FY2024AdvancedAnnual report

    「Series 11 stock acquisition rights Resolution date 18 July 2024 Eligible recipients and number (people) Company employees 31 (Note) 6 Number of stock acquisition rights (units) 1,135 (Note) 1 Number of shares underlying the stock acquisition rights (shares) 113,500 (Note) 1」

    Following the Series 10 stock acquisition rights, the Company granted Series 11 stock acquisition rights to 31 employees, covering 113,500 shares, under its employee stock option program.
  4. FY2024-Q3First statedAnnual report

    「1. Reasons for issuing stock acquisition rights as stock options To achieve long-term growth in the Company's performance and corporate value, stock acquisition rights are being issued to employees as stock options, with the aim of further increasing their motivation and morale and strengthening the Company's unity. (1) Allotment date of the stock acquisition rights: 1 April 2024 (2) Eligible recipients and number: 23 Company employees (3) Number of stock acquisition rights issued: 1,010 (5) Class and number of shares underlying the stock acquisition rights: 101,000 common shares of the Company (100 shares per stock acquisition right) (9) Exercise period of the stock acquisition rights 15 March 2026 to 13 March 2034」

    The Company introduced a program to issue 1,010 stock acquisition rights covering 101,000 common shares to 23 employees. The allotment was completed on 1 April 2024, and the exercise period runs from 15 March 2026 to 13 March 2034.
Moved together

"Regulatory approval for a digital therapeutic app for insomnia and preparations for insurance reimbursement" moved the same way as this thread, in the same document, in 4 of its 8 moves.

443333★123456
  1. ★This thread
  2. 1Regulatory approval for a digital therapeutic app for insomnia and preparations for insurance reimbursement4×
  3. 2Use of a clinical trial system implementing blockchain technology4×
  4. 3Securing a Proof of Concept for an Advance Care Planning Support App3×
  5. 4Stabilizing Platform Revenue by Increasing the Number of Companies That Continue to Use the Platform3×
  6. 5Delay to Part of the Recruitment Plan Due to Intensifying Competition for Talent3×
  7. 6Research and development, regulatory approval and insurance reimbursement for a therapeutic app in otolaryngology3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Susmed's next results are scheduled for 2026-11-06. Read the earnings preview It last moved in the General Meetings of Shareholders of 2026-09-04: "Advanced".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Strengthening Incentives to Improve Medium- to Long-Term Performance and Corporate Value Through the Issuance of Employee Stock Options | SUSMED,Inc. (4263) | Komori